Antibe Therapeutics

Antibe Therapeutics is a potential game changer in pain management

Antibe Therapeutics (CVE:ATE, OTCQB:ATBPF) CEO Dan Legault joined Steve Darling from Proactive Investors Vancouver to talk about a biotech company with a pipeline of drugs targeting pain and inflammation. Antibe's pipeline addresses significant unmet medical needs, especially concerning the safety and addictive properties of today's pain therapeutics. Legault also chatted with Proactive about a recently published paper in the British Journal of Pharmacology, providing extensive information about the successful Phase 2B safety trial for its lead drug.

Quick facts: Antibe Therapeutics

Price: $0.42

Market: TSX-V
Market Cap: $113.49 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics named herein, including the promotion by the Company of Antibe Therapeutics in any Content on the Site, the Company...



Antibe Therapeutics is looking to the future after successful past year

Antibe Therapeutics  (CVE:ATE-OTCQB:ATBPF) CEO Dan Legault joined Steve Darling from the Proactive Investors Toronto studio to discuss his recent letter to the shareholders in which he outlined the company’s last year. Legault also talked about the year ahead and the prep work they...

on 4/7/19

2 min read